Pharma Focus Asia
KP - Choose our fully recyclable blister films

Novel Talquetamab Developed for Relapsed or Refractory Multiple Myeloma

Janssen Pharmaceutical Companies developed novel talquetamab for the treatment of adult patients with relapsed or refractory multiple myeloma.

Talquetamab is a potential first-in-class, off-the-shelf, T-cell redirecting bispecific antibody targeting both GPRC5D, a novel drug target, on multiple myeloma cells and CD3 on T-cells.

The talquetamab is applicable for patients who underwent at least 4 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

Though there are therapies currently available for patients with relapsed or refractory multiple myeloma, there is a need for new targets and treatments due to the heterogeneity of the disease.

In Phase 1/2 clinical study, Talquetamab is being evaluated for the treatment of relapsed or refractory multiple myeloma (NCT03399799) and is also being explored in combination studies.

Multiple myeloma is an incurable blood cancer affecting white blood cells called plasma cells, commonly found in the bone marrow. In the year 2020, approximately 176,000 people were diagnosed with multiple myeloma globally and in 2022 it is expected over 34,000 people will be diagnosed with multiple myeloma and around 12,000 people will die due to this disease in U.S. Some of the common symptoms of multiple myeloma include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels, kidney problems or infections while few people diagnosed with multiple myeloma initially have no symptoms.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024